A controversy has erupted
in New Zealand over the funding
of the PHARMAC scheme, which
opposition politicians warn could
see Kiwis “potentially missing out
on life-saving medicines”.
District Health Boards in New
Zealand supported a $5 million
increase to PHARMAC’s budget
for 2015-16, whereas PHARMAC
had requested a NZ$10m increase
from NZ$795m to $806m to “meet
previous ministerial expectations
for new investments of $10m in
each year” said the Dominion Post.
PHARMAC chief executive
Steffan Crausaz said the agency
would continue to invest in new
medications from within its current
budget.
“The budget level is only one part
of the equation,” he said.
“Every year PHARMAC secures
between NZ$40m to $60m of
new price concessions and these
savings can also be used to meet
expectations,” he said.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Aug 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Aug 15
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.